BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22806877)

  • 21. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
    Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
    Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Inhibition of Hsp90 Protein by Benzothiazoloquinazolinequinones Is Enhanced in The Presence of Ascorbate. A Preliminary In Vivo Antiproliferative Study.
    Valderrama JA; Ríos D; Muccioli GG; Buc Calderon P; Benites J
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32093392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 9,10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases.
    Olszewski M; Stasevych M; Zvarych V; Maciejewska N
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2284113. PubMed ID: 38078360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers.
    Mijatovic T; Mathieu V; Gaussin JF; De Nève N; Ribaucour F; Van Quaquebeke E; Dumont P; Darro F; Kiss R
    Neoplasia; 2006 May; 8(5):402-12. PubMed ID: 16790089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer.
    Shang FF; Lu Q; Lin T; Pu M; Xiao R; Liu W; Deng H; Guo H; Quan ZS; Ding C; Shen QK
    J Med Chem; 2023 Sep; 66(18):12931-12949. PubMed ID: 37681508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.
    Salim KY; Maleki Vareki S; Danter WR; Koropatnick J
    Oncotarget; 2016 Jul; 7(27):41363-41379. PubMed ID: 27150056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition.
    Vriend LEM; van den Tempel N; Oei AL; L'Acosta M; Pieterson FJ; Franken NAP; Kanaar R; Krawczyk PM
    Oncotarget; 2017 Nov; 8(57):97490-97503. PubMed ID: 29228626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
    Socinski MA; Goldman J; El-Hariry I; Koczywas M; Vukovic V; Horn L; Paschold E; Salgia R; West H; Sequist LV; Bonomi P; Brahmer J; Chen LC; Sandler A; Belani CP; Webb T; Harper H; Huberman M; Ramalingam S; Wong KK; Teofilovici F; Guo W; Shapiro GI
    Clin Cancer Res; 2013 Jun; 19(11):3068-77. PubMed ID: 23553849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
    Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
    BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
    Lazenby M; Hills R; Burnett AK; Zabkiewicz J
    Leuk Res; 2015 Jun; 39(6):617-24. PubMed ID: 25882550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
    Goyal L; Wadlow RC; Blaszkowsky LS; Wolpin BM; Abrams TA; McCleary NJ; Sheehan S; Sundaram E; Karol MD; Chen J; Zhu AX
    Invest New Drugs; 2015 Feb; 33(1):128-37. PubMed ID: 25248753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
    Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
    Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic target Hsp90 and cancer hallmarks.
    Miyata Y; Nakamoto H; Neckers L
    Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heat shock protein 90 inhibitors in non-small-cell lung cancer.
    Pillai RN; Ramalingam SS
    Curr Opin Oncol; 2014 Mar; 26(2):159-64. PubMed ID: 24463348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.
    Taipale M; Krykbaeva I; Koeva M; Kayatekin C; Westover KD; Karras GI; Lindquist S
    Cell; 2012 Aug; 150(5):987-1001. PubMed ID: 22939624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.